Fractyl Health (GUTS) Operating Margin (2023 - 2024)
Fractyl Health (GUTS) reported Operating Margin of 840333.33% for Q4 2024, down 65489048.0% year-on-year from N/an in Q1 2024, and down 394.44% quarter-over-quarter from 169957.14% in Q3 2024.
Fractyl Health (GUTS) has 2 years of Operating Margin data on file, last reported at 840333.33% in Q4 2024.
- For the quarter ending Q4 2024, Operating Margin fell 65489048.0% year-over-year to 840333.33%; the trailing twelve-month figure through Dec 2024 stood at 100570.97% (down 5820763.0% YoY), and the FY2024 full-year result was 100570.97%, down 5820763.0% from the prior year.
- Operating Margin for Q4 2024 stood at 840333.33%, down from 169957.14% in the prior quarter.
- Across five years, Operating Margin topped out at 16493.06% in Q2 2023 and bottomed at 840333.33% in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 38.10% |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 17.83% |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 23.02% |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -840,333.33% |
| Sep 30, 2024 | -169,957.14% |
| Jun 30, 2024 | -53,453.49% |
| Mar 31, 2024 | -65,278.79% |
| Dec 31, 2023 | -185,442.86% |
| Sep 30, 2023 | -38,536.11% |
| Jun 30, 2023 | -16,493.06% |
| Mar 31, 2023 | -242,140.00% |